10x Genomics director awarded 8,829 RSUs

MATEO ALAN reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

MATEO ALAN reported acquisition or exercise transactions in this Form 4 filing.

10x Genomics, Inc. director Alan Mateo reported an equity compensation grant in the form of 8,829 restricted stock units (RSUs) for Class A Common Stock. Each RSU represents one share upon vesting. The award vests in four equal quarterly installments beginning on May 21, 2026, contingent on continued service.

Following this grant, Mateo directly holds 85,877 shares of Class A Common Stock, reflecting his updated equity stake in the company.

Insider Trade Summary

Grant/Award: 8,829 shares

Grant/Award 1 txn

Insider MATEO ALAN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	8,829	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 85,877 shares (Direct)

Footnotes (1)

1. F1. Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date.

Key Figures

RSUs granted: 8,829 RSUs Transaction price per share: $0.00 per share Shares held after transaction: 85,877 shares +2 more

5 metrics

RSUs granted 8,829 RSUs Equity award of Class A Common Stock RSUs

Transaction price per share $0.00 per share Non-cash RSU grant price

Shares held after transaction 85,877 shares Direct holdings of Class A Common Stock after grant

Vesting start date May 21, 2026 First quarterly vesting date for RSUs

Vesting pattern 1/4 each quarterly anniversary Four equal quarterly installments from May 21, 2026

Key Terms

restricted stock units ("RSUs"), Class A Common Stock, vesting, service provider

4 terms

restricted stock units ("RSUs") financial

"Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Class A Common Stock financial

"Each RSU represents a contingent right to receive one share of Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

vesting financial

"Each RSU represents a contingent right to receive one share ... upon vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

service provider financial

"subject to the Reporting Person continuing as a service provider through each such date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did 10x Genomics (TXG) director Alan Mateo report?

Alan Mateo reported receiving 8,829 restricted stock units (RSUs) of 10x Genomics Class A Common Stock as an equity compensation grant. These RSUs convert into shares as they vest over time, increasing his potential ownership stake if he remains a service provider.

How many RSUs did Alan Mateo receive from 10x Genomics (TXG)?

He received 8,829 RSUs, each representing a contingent right to one share of Class A Common Stock upon vesting. This non-cash award is part of his compensation and will translate into shares gradually as vesting conditions based on continued service are satisfied.

What is the vesting schedule for Alan Mateo’s 10x Genomics (TXG) RSUs?

The 8,829 RSUs vest in four equal quarterly installments starting May 21, 2026. One quarter of the units vests on each quarterly anniversary, provided Mateo continues as a service provider through each vesting date, aligning vesting with ongoing service to the company.

What are Alan Mateo’s holdings in 10x Genomics (TXG) after this RSU grant?

After the reported RSU grant, Alan Mateo directly holds 85,877 shares of 10x Genomics Class A Common Stock. This figure reflects his updated direct ownership position as reported in the filing, combining previously held shares with the newly granted equity award.

Does the 10x Genomics (TXG) RSU grant involve a purchase price?

The RSU grant shows a transaction price of $0.00 per share because RSUs are awarded as compensation, not purchased in the market. Shares are issued only if vesting conditions are met, so no cash changes hands at the time of the grant itself.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 07:24 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MATEO ALAN

(Last) (First) (Middle)

C/O 10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CALIFORNIA 94588

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/04/2026		A		8,829(1)	A	$0	85,877	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Randy Wu, as Attorney-in-Fact for Alan Mateo	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)